Sanofi India Limited
SANOFI · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹2,916.69.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- –ROE above 15%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-12%
- ✕Earnings growing-14%
- ✓Net margin ≥ 10%17.5%
- –Current ratio > 1.5
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 11.16
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (17.5%).
- •Financially solid — Altman Z 11.16.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Earnings contracting year on year.
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Nov
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.